Kangmei Pharma | 600518 - Cash And Equivalent


Kangmei Pharma reported CNY1.23B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Avita Medical AUD 10.24M 1.98M Dec/2025
Cspc Pharmaceutical CNY 7.57B 793.73M Jun/2025
Dianthus Therapeutics USD 627.67M 576.58M Mar/2026
Genomma Lab Internacional MXN 2.81B 264.13M Mar/2026
Hypermarcas BRL 1.65B 218.22M Dec/2025
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
IQVIA Holdings USD 1.95B 33M Mar/2026
Jiangsu Hengrui CNY 40.96B 591.41M Dec/2025
Kangmei Pharma CNY 1.23B 48.16M Mar/2026
Moderna USD 1.91B 687M Mar/2026
Organon & Co USD 1.12B 542M Mar/2026
Revvity USD 860.32M 59.54M Mar/2026
Sh Fosun Pharma CNY 13.1B 1.63B Dec/2025
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Viatris USD 1.8B 481.8M Mar/2026
Wuxi Apptec CNY 35.91B 773.93M Mar/2026
Xeris Pharmaceuticals USD 111.75M 708K Mar/2026
Zz Pientze Pharmaceu CNY 1.96B 186.63M Mar/2026